Biomerica (NASDAQ:BMRA) Director M. Huff Gary Purchases 31,250 Shares

Biomerica, Inc. (NASDAQ:BMRA) Director M. Huff Gary acquired 31,250 shares of the stock in a transaction that occurred on Thursday, August 20th. The stock was acquired at an average price of $1.60 per share, with a total value of $50,000.00. Following the completion of the transaction, the director directly owned 51,250 shares of the company’s stock, valued at $82,000. This trade represents a 156.25% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link.

Biomerica Stock Up 24.3%

Shares of Biomerica stock opened at $2.10 on Friday. The firm has a market cap of $6.49 million, a PE ratio of -2.36 and a beta of 0.35. Biomerica, Inc. has a 52 week low of $1.45 and a 52 week high of $3.24. The business’s fifty day simple moving average is $1.66 and its 200-day simple moving average is $1.99.

Institutional Investors Weigh In On Biomerica

A hedge fund recently bought a new stake in Biomerica stock. BlackRock Inc. acquired a new position in shares of Biomerica, Inc. (NASDAQ:BMRA) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 18,636 shares of the company’s stock, valued at approximately $33,000. BlackRock Inc. owned approximately 0.60% of Biomerica as of its most recent filing with the Securities & Exchange Commission. 22.28% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts recently weighed in on BMRA shares. Weiss Ratings downgraded shares of Biomerica from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, June 5th. Citizens Jmp assumed coverage on Biomerica in a research note on Tuesday, May 5th. They issued a “mkt outperform” rating and a $9.00 price objective for the company. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company has an average rating of “Sell” and an average target price of $9.00.

About Biomerica

Biomerica, Inc is a developer, manufacturer and marketer of in vitro diagnostic tests for clinical diagnostic, life science research and food safety applications. The company’s product portfolio includes enzyme-linked immunosorbent assays (ELISAs), lateral flow immunoassays, point-of-care devices and specialty reagents designed to aid in the detection and monitoring of gastrointestinal, metabolic and autoimmune conditions. Biomerica’s diagnostics are used by hospitals, clinical and reference laboratories, and research institutions seeking solutions for early disease detection and patient management.

Key offerings from Biomerica include serological tests for celiac disease and gluten intolerance, quantitative assays for colorectal cancer screening markers such as M2-PK, and a range of point-of-care kits for metabolic monitoring.